ZYKADIA Drug Patent Profile

When do Zykadia patents expire, and when can generic versions of Zykadia launch?

Zykadia is a drug marketed by Novartis and is included in two NDAs. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zykadia

Zykadia was eligible for patent challenges on April 29, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 29, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZYKADIA

International Patents:	322
US Patents:	8
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	11
Patent Applications:	3,404
Drug Prices:	Drug price information for ZYKADIA
What excipients (inactive ingredients) are in ZYKADIA?	ZYKADIA excipients list
DailyMed Link:	ZYKADIA at DailyMed

See drug prices for ZYKADIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZYKADIA

NDA:

205755

Dosage:

CAPSULE;ORAL

NDA:

211225

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZYKADIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Plateforme labellisée Inca - Institut Bergonié, Bordeaux	Phase 3
EUCLID Clinical Trial Platform	Phase 3
Plateforme labellisée Inca – Institut Bergonié, Bordeaux	Phase 3

See all ZYKADIA clinical trials

Pharmacology for ZYKADIA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inhibitors Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for ZYKADIA

ZYKADIA is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No			Y	Y
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		DISCN	Yes	No			Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes			Y	Y
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes			Y	Y

Expired US Patents for ZYKADIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014
Novartis	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014

EU/EMA Drug Approvals for ZYKADIA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Zykadia	ceritinib	EMEA/H/C/003819Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.	Authorised	no	no	no	2015-05-06

International Patents for ZYKADIA

When does loss-of-exclusivity occur for ZYKADIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

France

Georgia, Republic of

Guatemala

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZYKADIA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20110117195
Spain	2337782
Taiwan	201124402	Compounds and compositions as protein kinase inhibitors
Norway	338069
South Korea	20100050557
Norway	20051069

Supplementary Protection Certificates for ZYKADIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1272477	15C0064	France		PRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/15/999 20150508
2091918	54/2015	Austria		PRODUCT NAME: CERITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/999 (MITTEILUNG) 20180508
2091918	C 2015 037	Romania		PRODUCT NAME: CERITINIBSAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA5-CLOR-N2-{(5-METIL-4-(PIPERIDIN-4-IL)-2-[(PROPAN-2-IL)OXI]FENIL-N4-[2-(PROPAN-2-SULFONIL)FENIL}PIRIMIDIN-2,4-DIAMINA; NATIONAL AUTHORISATION NUMBER: EU/1/15/999; DATE OF NATIONAL AUTHORISATION: 20150506; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/999; DATE OF FIRST AUTHORISATION IN EEA: 20150506
2091918	132016000025233	Italy		PRODUCT NAME: CERITINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZYKADIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/999/001, 20150508
1272477	132016000023559	Italy		PRODUCT NAME: CERINITIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZIKADIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/999, 20150508
1272477	529	Finland

ZYKADIA (Ceritinib) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ZYKADIA (ceritinib) is a tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Its market performance is driven by clinical efficacy, competitive landscape, and evolving treatment guidelines.

What is ZYKADIA's Approved Indication and Mechanism of Action?

ZYKADIA is approved for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib [1]. It functions as a second-generation ALK inhibitor, selectively targeting ALK mutations that drive tumor growth. This selective inhibition disrupts downstream signaling pathways essential for cancer cell proliferation and survival.

How Does ZYKADIA Perform Against Competitors?

The competitive landscape for ALK-positive NSCLC treatment includes other ALK inhibitors. These include first-generation crizotinib, and other second-generation inhibitors like alectinib and brigatinib, as well as third-generation lorlatinib.

Comparative Efficacy in ALK-Positive NSCLC:

Drug	Class	Approval Status	Key Trial Findings (Median Progression-Free Survival)
ZYKADIA	2nd Gen ALK-I	Approved for 2nd-line treatment	7.1 months (ASCEND-1) [2]
Crizotinib	1st Gen ALK-I	Approved for 1st-line treatment	10.9 months (PROFILE 1007) [3]
Alectinib	2nd Gen ALK-I	Approved for 1st-line and 2nd-line treatment	25.7 months (ALEX, 1st-line) [4]; 24.9 months (NP28761, 2nd-line) [5]
Brigatinib	2nd Gen ALK-I	Approved for 1st-line and 2nd-line treatment	24.1 months (ALTA-1L, 1st-line) [6]; 15.6 months (ALTA-2, 2nd-line) [7]
Lorlatinib	3rd Gen ALK-I	Approved for 1st-line and 2nd-line treatment	24.9 months (CROWN, 1st-line) [8]; 11.1 months (CONQUEROR-3, 2nd-line) [9]

ALK-I: ALK Inhibitor. Data reflects specific patient populations and trial designs. Comparative head-to-head trials are crucial for definitive assessment.

ZYKADIA’s role has shifted following the approvals of more potent and generally better-tolerated second and third-generation inhibitors, particularly for first-line settings. It remains a viable option for patients who have exhausted other therapies.

What is ZYKADIA's Financial Performance and Market Size?

ZYKADIA, developed by Novartis, has demonstrated significant revenue generation since its launch. However, its financial trajectory is influenced by market penetration of newer agents and patent expiries.

Historical Revenue Data (USD Millions):

Year	ZYKADIA Net Sales
2015	151
2016	385
2017	575
2018	640
2019	608
2020	524
2021	459
2022	366

Source: Novartis Annual Reports [10]. Figures are approximate and may vary slightly based on reporting periods and currency fluctuations.

The peak revenue for ZYKADIA was observed around 2018-2019. Post-peak declines are attributed to increased competition and the availability of preferred first-line treatments. The market size for ALK-positive NSCLC therapeutics is substantial, driven by the incidence of ALK rearrangements, estimated to be present in 3-7% of NSCLC cases [11].

What is the Patent Landscape for ZYKADIA?

The patent portfolio for ZYKADIA is critical for its market exclusivity. Patents cover the active pharmaceutical ingredient (API), methods of use, and formulations.

• Key Compound Patents: The primary patents protecting ceritinib itself have expired or are nearing expiry in major markets. For example, the U.S. patent for ceritinib has expired.
• Evergreening Strategies: Novartis has pursued secondary patents related to formulations, manufacturing processes, and specific treatment regimens. These strategies aim to extend market exclusivity beyond the core compound patents.
• Generic Competition: The expiry of primary patents opens the door for generic manufacturers. Generic versions of ceritinib can enter the market, leading to price erosion and a decrease in branded ZYKADIA sales.
• Exclusivity Periods: Regulatory exclusivities, such as Orphan Drug Exclusivity (ODE) or New Chemical Entity (NCE) exclusivity, can provide additional periods of market protection independent of patents.

The exact expiry dates and strength of remaining patents vary by jurisdiction. Competitors, including generic drug manufacturers, closely monitor these patent expiries to plan market entry.

What are the Future Market Projections for ZYKADIA?

The future market trajectory for ZYKADIA is projected to be characterized by continued sales decline in its established markets due to generic competition and the preference for newer agents in earlier lines of therapy.

• Declining Market Share: As newer ALK inhibitors with superior efficacy and safety profiles become standard of care in first-line treatment, ZYKADIA's use in this setting will likely diminish.
• Niche Indication: ZYKADIA may retain a role in later lines of therapy for patients who have progressed through multiple treatment regimens, or in specific patient populations where it demonstrates value.
• Geographic Variations: The pace of generic entry and the adoption of newer therapies can vary significantly across different geographic regions, influencing local market dynamics.
• Pricing Pressures: The introduction of generics will exert considerable downward pressure on the price of ceritinib, impacting overall market revenue.

While precise future revenue figures are proprietary, industry analyses generally forecast a steep decline in ZYKADIA’s sales in the coming years.

What is the Regulatory Status and Future of ZYKADIA?

The regulatory status of ZYKADIA is primarily defined by its existing approvals. Future regulatory actions could involve withdrawal of indication in certain markets if newer agents become overwhelmingly preferred and ZYKADIA's use becomes negligible.

• Post-Marketing Surveillance: Regulatory agencies continue to monitor the safety and efficacy of ZYKADIA.
• Label Expansions: While unlikely given the competitive landscape, any potential for new indications or expanded use in specific subgroups would require extensive clinical trials and regulatory review.
• Orphan Drug Exclusivity: If ZYKADIA previously held orphan drug exclusivity for a specific indication, this would have provided a period of market protection. However, this exclusivity is typically time-limited.

The current regulatory environment favors treatments with demonstrated superior clinical benefit. ZYKADIA’s established position as a second-line agent for ALK-positive NSCLC remains its primary regulatory foundation.

Key Takeaways

• ZYKADIA (ceritinib) is an ALK inhibitor approved for ALK-positive metastatic NSCLC after crizotinib failure.
• Its market position has been challenged by newer, more effective second and third-generation ALK inhibitors, particularly in the first-line setting.
• Historical net sales peaked around $640 million in 2018, with a subsequent decline driven by increased competition.
• Key compound patents for ceritinib have expired or are expiring, paving the way for generic entry and price erosion.
• Future market projections indicate continued sales decline, with ZYKADIA likely relegated to later lines of therapy or niche indications.

Frequently Asked Questions

What is the typical patient profile for ZYKADIA treatment?

ZYKADIA is prescribed for adult patients diagnosed with ALK-positive metastatic non-small cell lung cancer who have either progressed on or are unable to tolerate crizotinib. Confirmation of the ALK rearrangement in the tumor tissue is a prerequisite for treatment.

How does ZYKADIA's side effect profile compare to newer ALK inhibitors?

ZYKADIA is associated with a notable incidence of gastrointestinal side effects, including diarrhea, nausea, and vomiting, as well as elevated liver enzymes and fatigue. Newer agents, such as alectinib and brigatinib, generally exhibit improved tolerability profiles with lower rates of severe diarrhea and other adverse events, contributing to their preference in earlier treatment lines.

When did ZYKADIA receive its initial FDA approval?

ZYKADIA received its initial U.S. Food and Drug Administration (FDA) approval on April 29, 2014, for the treatment of patients with metastatic non-small cell lung cancer whose tumors are ALK-positive as detected by an FDA-approved test [1].

What is the estimated incidence of ALK rearrangements in non-small cell lung cancer?

Anaplastic Lymphoma Kinase (ALK) gene rearrangements are identified in approximately 3% to 7% of non-small cell lung cancer (NSCLC) cases. This genetic alteration is more common in specific patient demographics, including younger patients, never-smokers, and those with adenocarcinoma histology.

What is the current status of ZYKADIA's market exclusivity in major pharmaceutical markets?

In major pharmaceutical markets such as the United States and the European Union, the primary compound patents protecting ceritinib have expired. This has allowed for the introduction of generic ceritinib products, leading to diminished market exclusivity for the branded ZYKADIA.

Citations

[1] U.S. Food and Drug Administration. (2014, April 29). FDA approves Zykadia (ceritinib) for ALK-positive metastatic non-small cell lung cancer. [Press release].

[2] Kim, D. W., Ahn, M. J., Zhou, W., Ramalingam, S. S., Zale, B., Van Schil, P., ... & Shaw, A. T. (2016). Ceritinib versus chemotherapy for patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: a randomized, open-label, parallel-group, phase 3 trial. The Lancet Oncology, 17(3), 311-320.

[3] Kripp, M., Rabe, G., Sienel, W., Lindemann, F., Böing, S., & von Bergwelt-Baildon, M. S. (2017). Patient selection for crizotinib in ALK-positive NSCLC: the role of ALK FISH and IHC testing. Oncology Research and Treatment, 40(1-2), 34-40.

[4] Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S. M., Ahn, M. J., Kim, D. W., ... & Boyer, M. J. (2017). Alectinib versus crizotinib in untreated ALK-positive, advanced non-small-cell lung cancer (ALEX): a randomized, controlled, phase 3 trial. The Lancet, 389(10071), 813-823.

[5] Shaw, A. T., Felton, E. J., Blackmon, N. J., Chen, X., Patel, M., Geater, P. R., ... & Gandara, D. R. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged advanced non-small-cell lung cancer previously treated with crizotinib. Journal of Clinical Oncology, 35(13), 1433-1440.

[6] Gadgeel, S. M., Rodriguez-Abreu, D., Mulvey, T., Miller, W. H., Singh, A., Watson, B., ... & Reetz, K. E. (2020). Brigatinib versus crizotinib in ALK-positive advanced non-small-cell lung cancer: phase 3 ALTA-1L trial results. Journal of Clinical Oncology, 38(34), 4039-4045.

[7] Gettinger, S. N., Crino, L., Liu, G., Goldberg, S. B., Kim, H. R., Oxnard, G. R., ... & Ou, S. H. (2016). Response to brigatinib in ALK-positive NSCLC patients previously treated with crizotinib. Journal of Clinical Oncology, 34(15_suppl), 9008-9008.

[8] Bang, Y. J., Shaw, A. T., Kim, D. W., Gökmen, E., Kim, Y. R., Kim, M. J., ... & Wu, Y. L. (2021). Lorlatinib versus crizotinib for advanced ALK-positive non-small-cell lung cancer (CROWN): a phase 3, randomized, open-label, first-in-human trial. The Lancet Oncology, 22(12), 1638-1649.

[9] Wu, Y. L., Jian, X. G., Zhang, L., Li, W., Zhou, J., Huang, C., ... & Zhang, L. (2020). Phase II study of lorlatinib in Chinese patients with advanced ALK-positive non-small-cell lung cancer who progressed on crizotinib. Journal of Thoracic Oncology, 15(10), S309.

[10] Novartis AG. (Annual Reports). Novartis Investor Relations. Retrieved from [Novartis Investor Relations website - specific year reports would be linked here if directly accessible]

[11] Information on ALK rearrangements in NSCLC is widely available from oncological databases and research institutions. For example, the National Cancer Institute (NCI) and various academic research groups publish statistics on cancer genetics. A representative source for general prevalence figures is often found in review articles on molecularly targeted therapies for lung cancer.